Inici › Mieloma múltiple › Carolina del Nord › Durham
Assaigs clínics de Mieloma múltiple a Durham, NC
37 estudis de Mieloma múltiple busquen participants en centres de Durham i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutantFase 3
- Research Site, Chapel Hill · a 10 mi
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
ReclutantFase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · a 10 mi
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ReclutantFase 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
ReclutantFase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · a 10 mi
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutantFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutantFase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 2
- University of North Carolina Medical Center, Chapel Hill · a 10 mi
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
ReclutantFase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · a 10 mi
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
ReclutantFase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · a 13 mi
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
ReclutantFase 1/2
- GSK Investigational Site, Chapel Hill · a 10 mi
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutantFase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutantFase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutantFase 3
- Research Site, Durham
- Research Site, Chapel Hill · a 10 mi
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Reclutant
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · a 10 mi
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ReclutantFase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · a 10 mi
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ReclutantFase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · a 10 mi
Selinexor and Backbone Treatments of Multiple Myeloma Patients
ReclutantFase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- University of North Carolina /ID# 251203, Chapel Hill · a 10 mi
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
ReclutantFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
ReclutantFase 2
- University of North Carolina (Data Collection Only), Chapel Hill · a 10 mi
Registry of Older Patients With Cancer
ReclutantEstudi observacional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ReclutantFase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
ReclutantFase 2
- University of North Carolina, Chapel Hill · a 10 mi
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
ReclutantFase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
ReclutantFase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · a 10 mi
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
ReclutantFase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · a 13 mi
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutantFase 1
- University of North Carolina, Chapel Hill · a 10 mi
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
ReclutantFase 1
- University of North Carolina, Chapel Hill · a 10 mi
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutantFase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · a 10 mi
Registry for Adults With Plasma Cell Disorders (PCD's)
ReclutantEstudi observacional
- North Carolina Cancer Hospital, Chapel Hill · a 10 mi
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
ReclutantEstudi observacional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutantFase 1
- Duke University Health System (DUHS), Durham
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- Rochester, MN24 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
- Seattle, WA22 estudis
Altres estudis a Durham
- Càncer de mama63 estudis
- Càncer (tots els tipus)58 estudis
- Càncer de pulmó de cèl·lules no petites39 estudis
- Càncer metastàtic33 estudis
- Leucèmia mieloide aguda33 estudis
- Càncer de pulmó32 estudis
- Càncer de pròstata32 estudis
- Càncer colorrectal28 estudis
- Leucèmia limfàtica crònica27 estudis
- Càncer d'ovari27 estudis
- Insuficiència cardíaca26 estudis
- Càncer de pàncrees24 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.